Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Durvalumab · 1 trial · 4 indications
combination of gemcitabine+nab-paclitaxel+propranolol+durvalumab+tremelimumab's objective response rate is greater than or equal to 50%
propranolol + durvalumab + tremelimumab objective response rate is greater than 45%
To demonstrate in unresectable BTC (gallbladder, cholangiocarcinoma of the biliary tracts including ampullary carcinomas) that the combination of gemcitabine + cisplatin + propranolol + durvalumab + tremelimumab's objective response rate is greater than 50%
| Arm | Type | Description |
|---|---|---|
| Pancreatic Cancer | EXPERIMENTAL | Durvalumab will be administered once every 4 weeks, in combination with gemcitabine + nab-paclitaxel (day 1/8/15) and continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients. |
| Hepatocellular Cancer | EXPERIMENTAL | Durvalumab will be administered once every 4 weeks in combination with continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients. |
| Biliary Tract Cancer | EXPERIMENTAL | Durvalumab will be administered once every 3 weeks, in combination with cisplatin + gemcitabine (day 1/8) and continuous propranolol. Tremelimumab will be given on day 1 of cycle 1, which may be repeated at the time of progression in eligible patients. |
| Name | Type | Description |
|---|---|---|
| Durvalumab | BIOLOGICAL | It is a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 with the PD-1. Durvalumab is known as a checkpoint inhibitor drug |
| Gemcitabine | DRUG | Gemcitabine is a nucleoside analog and a chemotherapeutic agent. As a prodrug, gemcitabine is transformed into its active metabolites that work by replacing the building blocks of nucleic acids during DNA elongation, arresting tumour growth and promoting apoptosis of malignant cells |
| Nab paclitaxel | DRUG | Nanoparticle albumin-bound (nab) paclitaxel is a form of paclitaxel which works as an antimicrotubule agent. Paclitaxel, the active ingredient in nab-paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This interferes with the normal dynamic reorganization of the microtubule network required for interphase and mitotic functions |
| Tremelimumab | BIOLOGICAL | Tremelimumab is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. |
| Propranolol | DRUG | Competitively blocks both β1 and β2 adrenergic receptors. |
| Cisplatin | DRUG | cisplatin has been associated with ability to crosslink with the urine bases on the DNA to form DNA adducts, preventing repair of the DNA leading to DNA damage and subsequently induces apoptosis within cancer cells. |
Inclusion Criteria: 1. Patients must be 18 years of age or older. 2. Body Weight \>30kg 3. Life expectancy of at least 12 weeks 4. Patients must have a diagnosis of histologically documented advanced pancreatic adenocarcinoma, hepatocellular carcinoma, or BTC not amenable to curative intent local t...
Top 20 of 68 competitors
Durvalumab is being studied in a Phase 2 clinical trial for the treatment of advanced hepatopancreaticobiliary tumors, which include pancreatic cancer, hepatocellular cancer, biliary tract cancer, and cholangiocarcinoma. The trial combines durvalumab with tremelimumab, propranolol, and chemotherapy. The study is currently recruiting participants in Canada.
Durvalumab is being developed by Avalon GloboCare Corp., a biopharmaceutical company. The company's stock ticker is ALBT. Durvalumab is a monoclonal antibody being investigated in oncology, specifically for pancreatic cancer and other hepatopancreaticobiliary tumors.
Durvalumab is currently in Phase 2 clinical development for pancreatic cancer. The ongoing trial, NCT05451043, is a Phase 2 study that is recruiting participants. It is an investigational drug and has not yet been approved by regulatory authorities for this indication.
Durvalumab is being evaluated in a Phase 2 clinical trial with the identifier NCT05451043. This study is titled "Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreaticobiliary Tumors (BLOCKED)." The trial is recruiting and has a planned enrollment of 62 participants in Canada.
Durvalumab is a monoclonal antibody, classified as a -mab (antibody) therapeutic. It is being studied in combination with other agents for the treatment of advanced hepatopancreaticobiliary tumors. The trial is biomarker-selected, meaning participants are chosen based on specific biomarkers.